ATXA Therapeutics receives EMA Orphan Drug Designation for NTP42
for the treatment of Pulmonary Arte
DUBLIN, IRELAND – February 23, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to the Company's lead clinical candidate NTP42 for the treatment of pulmonary arterial hypertension (PAH). The European Commission formally adopted this decision on